← SEC 公告列表 | IMUX SEC 公告 | IMMUNIC, INC.（IMUX）

重大事件 即時報告 8-K 2026-07-06

Immunic 行政總裁獲任命為董事 填補退休空缺

於 SEC 網站開啟原文

AI 繁中摘要

申報類型：8-K 日期：2026年6月29日 公司：Immunic, Inc.（納斯達克：IMUX） Immunic 董事會出現人事變動。董事 Tamar Howson 於2026年6月29日辭去薪酬委員會成員及董事職務，正式退休。公司強調她的離任並非因任何營運、政策或實務上的分歧，董事會對她的貢獻表示感謝。 為填補空缺，董事會經提名及企業管治委員會推薦，於2026年7月5日任命現任行政總裁 Erik Lundgren 為第二類董事，任期至2028年股東週年大會，或其繼任者獲選舉及確認資格為止。Lundgren 並未獲委任加入董事會任何委員會，亦不會因董事職務獲得額外酬金。他與公司之間已存在僱傭協議（先前已於2026年5月27日的8-K申報中披露），除此之外，並無其他須按規例 S-K 第404(a)條披露的交易。 對投資者的潛在影響：行政總裁兼任董事屬常見安排，有助強化管理層與董事會之間的溝通，但同時可能引發獨立性關注。由於 Lundgren 並未加入任何委員會（如薪酬或審計委員會），獨立董事的制衡仍屬完整。整體而言，此次變動屬平穩過渡，不影響公司日常運作或戰略方向。
展開英文正文 
false
 0001280776
 
 
 
 
 
 
 
 0001280776
 
 
 2026-06-29
 2026-06-29
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June
29, 2026

 

IMMUNIC, INC.

(Exact name of registrant as specified in its
charter)

 

 
 Delaware
 001-36201
 56-2358443

 
 (State or other jurisdiction

of incorporation)
 (Commission File Number)
 (IRS Employer Identification No.)

 
 

1200 Avenue of the Americas, Suite 200

New York, NY 10036

USA

(Address of principal executive offices)

 

Registrant’s telephone number, including
area code: (332) 255-9818

  

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 
 ☐
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
 ☐
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
 ☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
 ☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities registered pursuant to Section 12(b) of the Act:

 

 
 Title of each class
 Trading Symbol(s)
 Name of exchange on which registered

 
 Common Stock, par value $0.0001
 IMUX
 The Nasdaq Stock Market LLC

 
 

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. Yes ☐ No ☐

 

  

  

 

 

Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 29, 2026, Tamar Howson resigned as a member of the
Compensation Committee of the Board of Directors (the “Board”) of Immunic, Inc., a Delaware corporation (the
“Company”), and as a member of the Board, as Ms. Howson transitions into retirement. Ms. Howson’s
resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations,
policies, or practices. The Board and the Company are deeply grateful for Ms. Howson’s service, dedication, and contributions
to the Company.

 

In connection with Ms. Howson’s resignation, on
July 5, 2026, following the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Erik
Lundgren, the Company’s Chief Executive Officer, to serve as a Class II director of the Board until the 2028 annual meeting of
stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. 

 

There are no arrangements or understandings between Mr. Lundgren and
any other person pursuant to which Mr. Lundgren was appointed as a director. Mr. Lundgren has not been appointed to serve on any committee
of the Board. Mr. Lundgren will not receive any additional compensation for his service as a director. Mr. Lundgren is party to an employment
agreement with the Company, which was previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities
and Exchange Commission on May 27, 2026. Other than such employment agreement and compensation arrangements in connection with his service
as the Company’s Chief Executive Officer, there are no transactions involving Mr. Lundgren that would require disclosure under Item
404(a) of Regulation S-K.

 

  

  

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 
 Dated: July 6, 2026
 Immunic, Inc.

 
  
  
  

 
  
 By:
 /s/ Erik Lundgren

 
  
  
 Erik Lundgren

 
  
  
 Chief Executive Officer